Hypothyroidism and moderate subclinical hypothyroidism are associated with increased all-cause mortality independent of coronary heart disease risk factors: a PreCIS database study.

PubWeight™: 1.17‹?› | Rank: Top 10%

🔗 View Article (PMID 21745107)

Published in Thyroid on July 11, 2011

Authors

Christine McQuade1, Mario Skugor, Danielle M Brennan, Brian Hoar, Cindy Stevenson, Byron J Hoogwerf

Author Affiliations

1: Department of Endocrinology, Diabetes and Metabolism, Cleveland Clinic, Cleveland, Ohio 44195, USA.

Articles citing this

Thyroid status and 6-year mortality in elderly people living in a mildly iodine-deficient area: the aging in the Chianti Area Study. J Am Geriatr Soc (2013) 2.10

Thyroid functional disease: an under-recognized cardiovascular risk factor in kidney disease patients. Nephrol Dial Transplant (2014) 1.06

A review of the evidence for and against increased mortality in hypothyroidism. Nat Rev Endocrinol (2012) 1.01

Subclinical hypothyroidism: Controversies to consensus. Indian J Endocrinol Metab (2013) 0.93

Thyroid hormones and cardiovascular disease. Nat Rev Cardiol (2016) 0.93

Clinical outcomes of patients with hypothyroidism undergoing percutaneous coronary intervention. Eur Heart J (2016) 0.91

Subclinical hypothyroidism and survival: the effects of heart failure and race. J Clin Endocrinol Metab (2013) 0.90

Hypothyroidism and mortality among dialysis patients. Clin J Am Soc Nephrol (2012) 0.90

Excess mortality in patients diagnosed with hypothyroidism: a nationwide cohort study of singletons and twins. J Clin Endocrinol Metab (2013) 0.89

Restoration of cardiac tissue thyroid hormone status in experimental hypothyroidism: a dose-response study in female rats. Endocrinology (2013) 0.87

Hypothyroidism Is Associated With Coronary Endothelial Dysfunction in Women. J Am Heart Assoc (2015) 0.85

Thyroid dysfunction in the elderly. Nat Rev Endocrinol (2013) 0.85

Association of thyroid functional disease with mortality in a national cohort of incident hemodialysis patients. J Clin Endocrinol Metab (2015) 0.83

Low-dose T₃ replacement restores depressed cardiac T₃ levels, preserves coronary microvasculature and attenuates cardiac dysfunction in experimental diabetes mellitus. Mol Med (2014) 0.82

Duration of thyroid dysfunction correlates with all-cause mortality. the OPENTHYRO Register Cohort. PLoS One (2014) 0.81

Cardiovascular risk and quality of life in elderly people with mild thyroid hormone deficiency. Front Endocrinol (Lausanne) (2014) 0.78

Subclinical hypothyroidism and risk for incident ischemic stroke among postmenopausal women. Thyroid (2014) 0.77

Free thyroxine level as an independent predictor of infection-related mortality in patients on peritoneal dialysis: a prospective multicenter cohort study. PLoS One (2014) 0.77

Changes in the before and after thyroxine treatment levels of adipose tissue, leptin, and resistin in subclinical hypothyroid patients. Wien Klin Wochenschr (2015) 0.77

Prevalence of unknown thyroid disorders in a Sardinian cohort. Eur J Endocrinol (2014) 0.76

Serum cholesterol levels in middle-aged euthyroid subjects with positive thyroid peroxidase antibodies. Int J Clin Exp Med (2015) 0.75

The debate on treating subclinical hypothyroidism. Singapore Med J (2016) 0.75

What is the association of hypothyroidism with risks of cardiovascular events and mortality? A meta-analysis of 55 cohort studies involving 1,898,314 participants. BMC Med (2017) 0.75

Hemostasis in Hypothyroidism and Autoimmune Thyroid Disorders. Int J Endocrinol Metab (2017) 0.75

Pre-admission TSH levels predict long-term mortality in adults treated for hypothyroidism. Endocrine (2017) 0.75

Effects of thyroid hormone withdrawal on metabolic and cardiovascular parameters during radioactive iodine therapy in differentiated thyroid cancer. J Int Med Res (2016) 0.75

Pulmonary consequences of hypothyroidism. Ann Thorac Med (2017) 0.75

Association of thyroid peroxidase antibody and dyslipidemia in subclinical hypothyroidism. J Family Med Prim Care (2017) 0.75

Articles by these authors

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med (2006) 18.25

Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association. Diabetes Care (2008) 9.34

Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med (2010) 4.03

Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA (2008) 3.64

Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet (2012) 3.48

The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med (2007) 2.89

Teambuilding and leadership training in an internal medicine residency training program. J Gen Intern Med (2004) 2.67

Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care (2010) 2.42

Diminished global arginine bioavailability and increased arginine catabolism as metabolic profile of increased cardiovascular risk. J Am Coll Cardiol (2009) 2.35

An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial. Eur Heart J (2007) 2.31

Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Circulation (2010) 2.27

Serum uric acid is an independent predictor of all-cause mortality in patients at high risk of cardiovascular disease: a preventive cardiology information system (PreCIS) database cohort study. Arthritis Rheum (2008) 2.19

A truly deadly quartet: obesity, hypertension, hypertriglyceridemia, and hyperinsulinemia. Cleve Clin J Med (2002) 2.15

Relationship between metabolic syndrome and carotid intima-media thickness: cross-sectional comparison between psoriasis and psoriatic arthritis. Arthritis Care Res (Hoboken) (2014) 2.09

Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding. Ann Intern Med (2009) 1.76

Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation). Circulation (2008) 1.73

Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure. J Am Coll Cardiol (2003) 1.70

Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial. J Am Coll Cardiol (2007) 1.66

Lack of benefit from intravenous platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment for percutaneous interventions of aortocoronary bypass grafts: a pooled analysis of five randomized clinical trials. Circulation (2002) 1.65

Nutrition recommendations and interventions for diabetes--2006: a position statement of the American Diabetes Association. Diabetes Care (2006) 1.65

Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database. Diabetes Care (2010) 1.54

Risk score to predict serious bleeding in stable outpatients with or at risk of atherothrombosis. Eur Heart J (2010) 1.53

Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review. Clin Ther (2012) 1.51

The impact of left ventricular size on response to cardiac resynchronization therapy. Am Heart J (2011) 1.45

Targeted metabolomic evaluation of arginine methylation and cardiovascular risks: potential mechanisms beyond nitric oxide synthase inhibition. Arterioscler Thromb Vasc Biol (2009) 1.44

Heart rate and blood pressure responses to mental stress and clinical cardiovascular events in men and women after coronary artery bypass grafting: the Post Coronary Artery Bypass Graft (Post-CABG) biobehavioral study. Am Heart J (2003) 1.41

Angiographic changes in saphenous vein grafts are predictors of clinical outcomes. Am Heart J (2003) 1.41

Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting. Circulation (2004) 1.34

Systemic elevations of free radical oxidation products of arachidonic acid are associated with angiographic evidence of coronary artery disease. Free Radic Biol Med (2006) 1.33

Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes. Cardiovasc Diabetol (2011) 1.21

Calcium supplementation and bone mineral density in females from childhood to young adulthood: a randomized controlled trial. Am J Clin Nutr (2005) 1.21

Impact of body mass index on outcome after percutaneous coronary intervention (the obesity paradox). Am J Cardiol (2002) 1.19

Development of renal disease in people at high cardiovascular risk: results of the HOPE randomized study. J Am Soc Nephrol (2003) 1.18

Lipoprotein(a) levels and long-term cardiovascular risk in the contemporary era of statin therapy. J Lipid Res (2010) 1.18

Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study. Cardiovasc Diabetol (2010) 1.17

In-hospital initiation of lipid-lowering therapy after coronary intervention as a predictor of long-term utilization: a propensity analysis. Arch Intern Med (2003) 1.17

The lipid accumulation product and all-cause mortality in patients at high cardiovascular risk: a PreCIS database study. Obesity (Silver Spring) (2009) 1.15

The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Am Heart J (2008) 1.10

Managing type 2 diabetes: going beyond glycemic control. J Manag Care Pharm (2008) 1.08

Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Am Heart J (2008) 1.07

Optimal timing for the initiation of pre-treatment with 300 mg clopidogrel before percutaneous coronary intervention. J Am Coll Cardiol (2006) 1.02

Subclinical myocardial necrosis and cardiovascular risk in stable patients undergoing elective cardiac evaluation. Arterioscler Thromb Vasc Biol (2009) 1.02

Clinical utility of waist circumference in predicting all-cause mortality in a preventive cardiology clinic population: a PreCIS Database Study. Obesity (Silver Spring) (2009) 1.01

Association of triglyceride-to-HDL cholesterol ratio with heart rate recovery. Diabetes Care (2004) 0.99

Effects of vitamin E on cardiovascular outcomes in people with mild-to-moderate renal insufficiency: results of the HOPE study. Kidney Int (2004) 0.98

Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience. Am Heart J (2013) 0.97

Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study. Am J Kidney Dis (2003) 0.91

Relation of hemoglobin A1c to left ventricular relaxation in patients with type 1 diabetes mellitus and without overt heart disease. Am J Cardiol (2003) 0.90

Safety and tolerability of acarbose in the treatment of type 1 and type 2 diabetes mellitus. Clin Drug Investig (2005) 0.90

Comprehensive peroxidase-based hematologic profiling for the prediction of 1-year myocardial infarction and death. Circulation (2010) 0.90

Prolonged dual antiplatelet therapy after percutaneous coronary intervention reduces ischemic events without affecting the need for repeat revascularization: insights from the CREDO trial. J Invasive Cardiol (2007) 0.89

Thyroid-stimulating hormone receptor messenger ribonucleic acid measurement in blood as a marker for circulating thyroid cancer cells and its role in the preoperative diagnosis of thyroid cancer. J Clin Endocrinol Metab (2006) 0.88

Impact of exercise on heart rate recovery. Circulation (2011) 0.87

Fate of individuals with ischemic amputations in the REACH Registry: three-year cardiovascular and limb-related outcomes. Atherosclerosis (2012) 0.87

Effects of exenatide on kidney function, adverse events, and clinical end points of kidney disease in type 2 diabetes. Am J Kidney Dis (2013) 0.85

Emerging cardiovascular risk factors that account for a significant portion of attributable mortality risk in chronic kidney disease. Am J Cardiol (2008) 0.85

Giant invasive pituitary prolactinoma with falsely low serum prolactin: the significance of 'hook effect'. J Neurooncol (2006) 0.85

Gender differences in utilization of effective cardiovascular secondary prevention: a Cleveland clinic prevention database study. J Womens Health (Larchmt) (2008) 0.84

Cardiovascular ischemic event rates in outpatients with symptomatic atherothrombosis or risk factors in the united states: insights from the REACH Registry. Crit Pathw Cardiol (2009) 0.84

Association of SF-36 with coronary artery disease risk factors and mortality: a PreCIS study. Prev Cardiol (2010) 0.84

Is there a clinically significant interaction between calcium channel antagonists and clopidogrel?: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Circ Cardiovasc Interv (2012) 0.83

The utility of peripheral thyrotropin mRNA in the diagnosis of follicular neoplasms and surveillance of thyroid cancers. Surgery (2007) 0.82

Relationship between baseline inflammatory markers, antiplatelet therapy, and adverse cardiac events after percutaneous coronary intervention: an analysis from the clopidogrel for the reduction of events during observation trial. Circ Cardiovasc Interv (2009) 0.82

Association of dyslipidemia and effects of statins on nonmacrovascular diseases. Clin Ther (2004) 0.81

Use of concomitant glucose-lowering therapies and associated treatment results observed in clinical trials of twice-daily exenatide. Endocr Pract (2012) 0.81

Risk factors for low bone mass in patients with ulcerative colitis following ileal pouch-anal anastomosis. Am J Gastroenterol (2009) 0.81

Effect of clopidogrel on the rate and functional severity of stroke among high vascular risk patients: a prespecified substudy of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) trial. Stroke (2010) 0.80

Relation of albumin/creatinine ratio to C-reactive protein and to the metabolic syndrome. Am J Cardiol (2003) 0.78

Exenatide once weekly for the treatment of type 2 diabetes mellitus: clinical results in subgroups of patients using different concomitant medications. Postgrad Med (2012) 0.78

Successful treatment of sulfonylurea-induced prolonged hypoglycemia with use of octreotide. Endocr Pract (2007) 0.78

High-sensitivity C-reactive protein and clopidogrel treatment in patients at high risk of cardiovascular events: a substudy from the CHARISMA trial. Heart (2011) 0.77

Clinical outcomes of concomitant therapy of exenatide twice daily and basal insulin in patients with type 2 diabetes mellitus: a retrospective database analysis in the United States. Endocr Pract (2012) 0.77

Coronary artery bypass graft surgery and cognitive performance. Am J Crit Care (2006) 0.77

Double jeopardy of renal insufficiency and anemia in patients undergoing percutaneous coronary interventions. Am J Cardiol (2004) 0.77

Coronary endothelium-dependent vasoreactivity and atheroma volume in subjects with stable, minimal angiographic disease versus non-ST-segment-elevation myocardial infarction: an intravascular ultrasound study. Circ Cardiovasc Imaging (2013) 0.77

Ectopic adrenocorticotropic hormone syndrome caused by metastatic carcinoma of the prostate: therapeutic response to ketoconazole. Endocr Pract (2004) 0.76

Quality of life after coronary artery bypass graft: results from the POST CABG Trial. Chest (2004) 0.76

Relation of diurnal blood pressure variation and triglyceride-to-high-density lipoprotein cholesterol ratio in patients without diabetes mellitus. Am J Cardiol (2005) 0.76

Elevated international normalized ratio in the ED: clinical course and physician adherence to the published recommendations. Am J Emerg Med (2005) 0.76

Hypoglycemia in patients with type 2 diabetes using concomitant exenatide BID and long-acting insulin therapy. J Med Econ (2011) 0.76

Coronary atheroma composition and its association with segmental endothelial dysfunction in non-ST segment elevation myocardial infarction: novel insights with radiofrequency (iMAP) intravascular ultrasonography. Int J Cardiovasc Imaging (2014) 0.75

A DASH-like diet can decrease cardiovascular risk, but barriers to implementation exist. Cleve Clin J Med (2004) 0.75

HgbA1c and glucose control: we cannot play it straight with patients. J Lab Clin Med (2006) 0.75

Reply: To PMID 23983044. Arthritis Care Res (Hoboken) (2014) 0.75

Cholesterol guidelines update: more aggressive therapy for higher-risk patients. Cleve Clin J Med (2005) 0.75

Comparison of clinical trial outcome patterns in patients following acute coronary syndromes and in patients with chronic stable atherosclerosis. Clin Cardiol (2014) 0.75

High school body mass index and body mass index at entry to a cardiac disease risk prevention clinic and the association to all-cause mortality and coronary heart disease: a PreCIS database study. J Cardiovasc Nurs (2010) 0.75